Clinical Trials
46
5 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1900
Active, not recruiting
2
4.3%
Completed
34
73.9%
Not yet recruiting
3
6.5%
Recruiting
3
6.5%
Terminated
2
4.3%
Withdrawn
2
4.3%
No approval data available
- Anthropic opened a research preview of its Model Hardware Standard (MHS), the company's first tool designed to operate in the physical world, enabling AI agents like Claude to control scientific equipment and automate experiments. - Genentech used MHS and Claude to autonomously optimize fluid dynamics for a BCA protein assay, with Claude independently determining optimal flow rates of ~140 µL/s for water and 10 µL/s for BSA. - Carnegie Mellon University researchers ran serial dilution dose-response experiments roughly three times faster using MHS, achieving a usable fit (R² > 0.98) after an autonomous rerun with no human input. - MHS is being tested with labs and manufacturers including HHMI Janelia, Carnegie Mellon, Genentech, and QuEra, ahead of a planned IPO that could value Anthropic at $2 trillion.
- Carnegie Mellon University researchers are advancing "cognitive AI," systems modeled on human decision-making that augment rather than replace human judgment and accountability. - In a radiology context, pairing a human radiologist with machine learning AI improved cancer-detection sensitivity by 2.6 percentage points across nearly 1.2 million mammograms. - Cognitive AI models can reach up to 95% alignment in predicting an individual's decisions after observing only a few dozen choices in controlled tasks. - Researchers emphasize designing human-AI teams around error consequences, trust, and goal alignment rather than treating AI as a one-size-fits-all replacement.
- The Richard King Mellon Foundation has committed up to $25 million to launch Rare Ventures, a first-of-its-kind venture philanthropy platform for accelerating rare disease therapies. - The initiative unites Carnegie Mellon University, the University of Pittsburgh, UPMC, Stanford Medicine, ElevateBio, and the EB Research Partnership to combine AI, clinical research, and therapeutic development. - More than 400 million people worldwide live with a rare disease, yet approximately 95% of the 10,000+ rare diseases lack an approved treatment. - Rare Ventures builds on EBRP's 14-year track record, which helped fund over 180 research projects and contributed to three FDA-approved therapies for epidermolysis bullosa.
- A Science study found that the three-dimensional organization of the genome differs in brain cells of people with Alzheimer's disease versus unaffected individuals. - Researchers combined single-cell GAGE-seq, spatial transcriptomics, and a new deep learning model called Hicformer to link genome folding with gene activity. - Alzheimer's cells showed 'increased compartment mingling,' more long-range and fewer short-range DNA contacts, and reduced overall gene activity. - The findings position higher-order chromatin alterations alongside amyloid-beta plaques and tau tangles as part of Alzheimer's molecular pathology.
- Researchers at Rice University, Carnegie Mellon University, and Northwestern University have developed HOBIT, a wireless implantable device that generates oxygen locally to support high-density cell clusters for drug production. - The device achieved six times higher cell densities than conventional approaches and maintained 65% cell viability after 30 days compared to 20% in control devices without oxygenation. - HOBIT successfully produced three different biologic molecules simultaneously, including antibodies, hormones, and GLP-1-like molecules, demonstrating potential for treating multiple diseases including diabetes. - The compact, gum-sized device integrates an electrocatalytic oxygenator, battery, and electronics into a fully wireless system that can be remotely controlled and placed under the skin via minimally invasive surgery.
- Northwestern University researchers have developed HOBIT, an implantable device containing engineered cells that continuously produce multiple biologic drugs inside the body, including anti-HIV antibodies, diabetes treatments, and appetite-regulating hormones. - The device integrates oxygen-producing bioelectronics to overcome the critical challenge of cell survival in implants, achieving cell densities six times higher than conventional approaches and maintaining 65% cell viability after 30 days. - In animal studies, the gum-sized wireless device successfully delivered sustained levels of three different biologics with varying half-lives for 30 days, while control devices without oxygenation failed by day seven. - This breakthrough could transform chronic disease treatment by eliminating the need for patients to remember daily medications, with future applications planned for pancreatic cell therapies and larger animal model testing.
- Researchers at Carnegie Mellon University have created AggreBots, microscale living robots made entirely from human lung cells that use natural cilia for propulsion and movement control. - The novel modular assembly strategy allows precise control over biobot motility patterns by combining functional and non-functional cell spheroids in specific arrangements. - These biodegradable and biocompatible biobots could enable personalized therapeutic delivery without immune rejection risks, with potential applications in lung cancer treatment and cystic fibrosis therapy. - The technology represents a significant advancement over traditional synthetic nanorobots by eliminating the need for external power sources and reducing biocompatibility concerns.
- FluidForm Bio has developed an advanced FRESH 3D bioprinting technique using sacrificial gelatin microparticles that maintains cell viability five times deeper than traditional methods, addressing a critical limitation in tissue engineering. - The company recently strengthened its intellectual property with USPTO Patent No. 12,215,202 B2, protecting core innovations in their bioprinting platform that enables clinical-grade manufacturing of functional human tissue. - FluidForm's lead program focuses on type 1 diabetes treatment through subcutaneous implantation of bioprinted insulin-producing beta cells, offering a less invasive alternative with improved retrievability and reduced surgical risks.
- Rice University received a $34.9 million grant to develop ROGUE, a bioelectronic implant for type 2 diabetes and obesity treatment, designed to improve patient adherence. - ROGUE will house cells that produce therapies in response to the patient’s needs, offering a cost-effective alternative to frequent injections of biologics like GLP-1 RAs. - The implantable device will use closed-loop bioelectronics to monitor and adjust drug production, requiring only weekly recharging via a wearable device. - Clinical trials are planned to begin in the fifth year of the six-year project, aiming for rapid and cost-effective deployment via a minimally invasive outpatient procedure.
